Mary Fenton - Talaris Therapeutics CFO Treasurer
| TALSDelisted Stock | USD 2.98 0.10 3.25% |
Insider
Mary Fenton is CFO Treasurer of Talaris Therapeutics
| Age | 59 |
| Phone | 502 398 9250 |
| Web | https://talaristx.com |
Mary Fenton Latest Insider Activity
Tracking and analyzing the buying and selling activities of Mary Fenton against Talaris Therapeutics stock is an integral part of due diligence when investing in Talaris Therapeutics. Mary Fenton insider activity provides valuable insight into whether Talaris Therapeutics is net buyers or sellers over its current business cycle. Note, Talaris Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Talaris Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Mary Fenton over a year ago Acquisition by Mary Fenton of 150000 shares of Talaris Therapeutics subject to Rule 16b-3 |
Talaris Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2281) % which means that it has lost $0.2281 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4164) %, meaning that it created substantial loss on money invested by shareholders. Talaris Therapeutics' management efficiency ratios could be used to measure how well Talaris Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Talaris Therapeutics currently holds 2.88 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Talaris Therapeutics has a current ratio of 28.34, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Talaris Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA MD | Vor Biopharma | 47 | |
| Michelle Doig | Nuvation Bio | 46 | |
| Oleg Nodelman | Nuvation Bio | 44 | |
| Gary Hattersley | Nuvation Bio | 57 | |
| Jeffrey Rona | Ovid Therapeutics | 56 | |
| Zoology Dphil | Ovid Therapeutics | 69 | |
| Sergey Yurasov | Nuvation Bio | 51 | |
| Ted Jenkins | Spero Therapeutics | N/A | |
| Jeffrey Trigilio | Cullinan Oncology LLC | 40 | |
| Claude MD | Ovid Therapeutics | 71 | |
| Nicole White | Assembly Biosciences | N/A | |
| Susannah Walpole | Spero Therapeutics | N/A | |
| Aya Jakobovits | Adicet Bio | 69 | |
| DPHIL DPhil | CytomX Therapeutics | 57 | |
| DSc FACP | Ovid Therapeutics | 65 | |
| FMEDSCI MD | Achilles Therapeutics PLC | 49 | |
| Thomas Templeman | Nuvation Bio | 60 | |
| MBA BS | CytomX Therapeutics | 45 | |
| Robert Coutts | Achilles Therapeutics PLC | 40 | |
| David Hanley | Nuvation Bio | 54 | |
| MBA MD | Cullinan Oncology LLC | 51 | |
Management Performance
| Return On Equity | -0.42 | |||
| Return On Asset | -0.23 |
Talaris Therapeutics Leadership Team
Elected by the shareholders, the Talaris Therapeutics' board of directors comprises two types of representatives: Talaris Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Talaris. The board's role is to monitor Talaris Therapeutics' management team and ensure that shareholders' interests are well served. Talaris Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Talaris Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nancy MD, Chief Officer | ||
| Eric Gornstein, Head Planning | ||
| Suzanne Tollerud, VP Devel | ||
| Michael Zdanowski, Chief Officer | ||
| JD LLB, CEO and President | ||
| Suzanne MD, Member Founder | ||
| Mary Fenton, CFO Treasurer | ||
| Farah Natoli, Head Management | ||
| Colby Suire, Head RD | ||
| Andrew Farnsworth, Chief Officer |
Talaris Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Talaris Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.42 | |||
| Return On Asset | -0.23 | |||
| Current Valuation | (28.92 M) | |||
| Shares Outstanding | 42.81 M | |||
| Shares Owned By Insiders | 11.90 % | |||
| Shares Owned By Institutions | 77.67 % | |||
| Number Of Shares Shorted | 340.1 K | |||
| Price To Book | 0.28 X | |||
| EBITDA | (74.31 M) | |||
| Net Income | (73.89 M) |
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in Talaris Stock
If you are still planning to invest in Talaris Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talaris Therapeutics' history and understand the potential risks before investing.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |